Literature DB >> 26682991

Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.

Amy S Joehlin-Price1, Julie A Stephens2, Jianying Zhang2, Floor J Backes3, David E Cohn3, Adrian A Suarez4.   

Abstract

BACKGROUND: Obesity is a main risk factor for endometrial carcinoma (EC). Insulin-like growth factor 1 receptor (IGF1R) expression may influence this association.
METHODS: IGF1R IHC was performed on a tissue microarray with 894 EC and scored according to the percentage and intensity of staining to create immunoreactivity scores, which were dichotomized into low and high IGF1R expression groups. Logistic regression modeling assessed associations with body mass index (BMI), age, histology, pathologic extent of disease (pT), and lymph node metastasis (pN). Overall survival (OS) and disease-free survival (DFS) were compared between IGF1R expression groups using Kaplan-Meier curves and log-rank tests.
RESULTS: The proportion of patients with high IGF1R expression increased as BMI (<30, 30-39, and 40+ kg/m(2)) increased (P = 0.002). The adjusted odds of having high IGF1R expression was 1.49 [95% confidence interval (CI), 1.05-2.10, P = 0.024] for patients with BMI 30 to 39 kg/m(2) compared with <30 kg/m(2) and 1.62 (95% CI, 1.13-2.33, P = 0.009) for patients with BMI 40+ kg/m(2) compared with <30 kg/m(2). High IGF1R expression was associated with pT and pN univariately and with pT after adjusting for BMI, pN, age, and histologic subtype. DFS and OS were better with high IGF1R expression, P = 0.020 and P = 0.002, respectively, but DFS was not significant after adjusting for pT, pN, and histologic subtype of the tumor.
CONCLUSIONS: There is an association between BMI and EC IGF1R expression. Higher IGF1R expression is associated with lower pT and better DFS and OS. IMPACT: These findings suggest a link between IGF1R EC expression and obesity, as well as IGF1R expression and survival. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26682991      PMCID: PMC5075967          DOI: 10.1158/1055-9965.EPI-15-1145

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  44 in total

1.  Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins.

Authors:  L Kanter-Lewensohn; A Dricu; L Girnita; J Wejde; O Larsson
Journal:  Growth Factors       Date:  2000       Impact factor: 2.511

2.  Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype.

Authors:  Y Xie; B Skytting; G Nilsson; B Brodin; O Larsson
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

3.  Insulin-like growth factor I receptors in normal and neoplastic human endometrium.

Authors:  F Talavera; R K Reynolds; J A Roberts; K M Menon
Journal:  Cancer Res       Date:  1990-05-15       Impact factor: 12.701

4.  Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative.

Authors:  Katherine W Reeves; Gebra Cuyun Carter; Rebecca J Rodabough; Dorothy Lane; S Gene McNeeley; Marcia L Stefanick; Electra D Paskett
Journal:  Gynecol Oncol       Date:  2011-02-15       Impact factor: 5.482

5.  Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium.

Authors:  Adrienne S McCampbell; Russell R Broaddus; David S Loose; Peter J A Davies
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

6.  Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study.

Authors:  James V Lacey; Nancy Potischman; M Patricia Madigan; Michael L Berman; Rodrigue Mortel; Leo B Twiggs; Rolland J Barrett; George D Wilbanks; John R Lurain; Capri-Mara Fillmore; Mark E Sherman; Louise A Brinton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-04       Impact factor: 4.254

7.  Influence of body mass index on prognosis in gynecological malignancies.

Authors:  Karsten Münstedt; Mathias Wagner; Uwe Kullmer; Andreas Hackethal; Folker E Franke
Journal:  Cancer Causes Control       Date:  2008-04-08       Impact factor: 2.506

8.  A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.

Authors:  Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Joann E Manson; Jixin Li; Tiffany G Harris; Thomas E Rohan; Xiaonan Xue; Gloria Y F Ho; Mark H Einstein; Robert C Kaplan; Robert D Burk; Judith Wylie-Rosett; Michael N Pollak; Garnet Anderson; Barbara V Howard; Howard D Strickler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

Review 9.  Insulin-like growth factors and cancer.

Authors:  Gregor Fürstenberger; Hans-Jörg Senn
Journal:  Lancet Oncol       Date:  2002-05       Impact factor: 41.316

10.  Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk.

Authors:  E Weiderpass; K Brismar; R Bellocco; H Vainio; R Kaaks
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

View more
  8 in total

1.  The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion: A Single Institution Report of 464 Consecutive FIGO Grade 1 Endometrial Endometrioid Adenocarcinomas.

Authors:  Amy S Joehlin-Price; Kelsey E McHugh; Julie A Stephens; Zaibo Li; Floor J Backes; David E Cohn; David W Cohen; Adrian A Suarez
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

Review 2.  Antioxidative, Anti-Inflammatory, Anti-Obesogenic, and Antidiabetic Properties of Tea Polyphenols-The Positive Impact of Regular Tea Consumption as an Element of Prophylaxis and Pharmacotherapy Support in Endometrial Cancer.

Authors:  Piotr Olcha; Anna Winiarska-Mieczan; Małgorzata Kwiecień; Łukasz Nowakowski; Andrzej Miturski; Andrzej Semczuk; Bożena Kiczorowska; Krzysztof Gałczyński
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

3.  Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer.

Authors:  Gloria S Huang; Marc J Gunter; Melissa A Merritt; Howard D Strickler; Alan D Hutson; Mark H Einstein; Thomas E Rohan; Xiaonan Xue; Mark E Sherman; Louise A Brinton; Herbert Yu; David S Miller; Nilsa C Ramirez; Heather A Lankes; Michael J Birrer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-02-23       Impact factor: 4.090

4.  Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival.

Authors:  Mojca Humar; Izidor Kern; Gregor Vlacic; Vedran Hadzic; Tanja Cufer
Journal:  Radiol Oncol       Date:  2017-04-26       Impact factor: 2.991

Review 5.  The Role of Metabolic Syndrome in Endometrial Cancer: A Review.

Authors:  Xiao Yang; Jianliu Wang
Journal:  Front Oncol       Date:  2019-08-08       Impact factor: 6.244

Review 6.  The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer.

Authors:  Kaja Michalczyk; Natalia Niklas; Małgorzata Rychlicka; Aneta Cymbaluk-Płoska
Journal:  Diagnostics (Basel)       Date:  2021-03-11

7.  Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis.

Authors:  Lauren McVicker; Christopher R Cardwell; Lauren Edge; W Glenn McCluggage; Declan Quinn; James Wylie; Úna C McMenamin
Journal:  BMC Cancer       Date:  2022-04-20       Impact factor: 4.638

8.  PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer.

Authors:  Wendell Jones; David Tait; Chad Livasy; Mahrukh Ganapathi; Ram Ganapathi
Journal:  NAR Cancer       Date:  2022-09-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.